## **AMENDMENTS TO THE CLAIMS**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1-99. (Cancelled)

100. (Currently amended) A nucleic acid encoding a chimeric transcriptional regulatory protein that comprises:

at least two heterologous nucleic acid binding domains, at least one of which is a zinc finger, wherein each nucleic acid binding domain binds a portion of a composite nucleotide sequence; and

a transcriptional regulatory domain, wherein the chimeric transcriptional regulatory protein (a) binds preferentially to the composite nucleotide sequence over any of said portions thereof, and (b) when bound to the composite nucleotide sequence, regulates transcription thereof from an operatively linked promoter.

- 101. (Currently amended) The nucleic acid of claim 100, wherein the <u>at least two</u> heterologous nucleic acid binding domains include at least two zinc fingers.
- 102. (Currently amended) The nucleic acid of claim 100, wherein the chimeric transcriptional regulatory protein comprises a third nucleic acid binding domains include at least a second nucleic acid binding domain selected from the group consisting of helix-loop-helix domains, helix-turn-helix domains, basic domains, zinc fingers, and combinations thereof.
- 103. (Previously presented) The nucleic acid of claim 100, wherein the transcriptional regulatory domain activates transcription.
- 104. (Previously presented) The nucleic acid of claim 100, wherein the transcriptional regulatory domain represses transcription.
- 105. (Previously presented) The nucleic acid of claim 100, wherein at least one nucleic acid binding domain is selected from the group consisting of helix-loop-helix domains, helix-turn-

Attorney Docket No.: 2003028-0051 Client Reference: MIT 6834/Ariad 022 US helix domains, basic domains, and combinations thereof.

106. (Previously presented) The nucleic acid of claim 100, wherein the zinc finger is from a protein selected from the group consisting of transcription factor IIIA, SW15, Krüppel,

Hunchback, and a steroid receptor.

107. (Previously presented) The nucleic acid of claim 100, wherein the zinc finger is from

Zif268.

108. (Previously presented) The nucleic acid of claim 100, wherein the at least two nucleic

acid binding domains are separated by at least one amino acid.

109-114. (Cancelled)

115. (Currently amended) A vector comprising a nucleic acid of claim 100 any one of

claims 100-108 and 120-124.

116. (Previously presented) The vector of claim 115, further comprising expression control

sequences permitting gene expression in eukaryotic cells.

117. (Currently amended) A kit comprising a vector of claim 115 and a gene operably

linked to a composite binding site nucleotide sequence to which the chimeric transcriptional

regulatory protein encoded by the nucleic acid binds.

118. (Cancelled)

119. (Currently amended) A method for modulating expression of a gene in a cell,

comprising:

providing a cell containing a chimeric DNA binding element composite nucleotide

sequence operatively linked to a promoter which is operatively linked to the gene; and

expressing the nucleic acid of elaim 100 any one of claims 100-108 and 120-124 in the

Attorney Docket No.: 2003028-0051 Client Reference: MIT 6834/Ariad 022 US cell, such that the chimeric transcriptional regulatory protein is produced, binds to the chimeric DNA binding element composite nucleotide sequence, and regulates transcription of the gene from the promoter.

- 120. (New) The nucleic acid of claim 100, wherein the chimeric transcriptional regulatory protein displays a binding specificity that is distinct from the binding specificity of the individual nucleic acid binding domains.
- 121. (New) The nucleic acid of claim 100, wherein the chimeric transcriptional regulatory protein binds preferentially to the composite nucleotide sequence over any of said portions thereof.
- 122. (New) The nucleic acid of claim 100, wherein the at least two nucleic acid binding domains are separated by 1, 2 or 4 amino acids.
- 123. (New) The nucleic acid of claim 100, wherein the at least two nucleic acid binding domains are separated by a distance of less than about 50 Å.
- 124. (New) The nucleic acid of claim 100, wherein the at least two nucleic acid binding domains are separated by a distance of less than about 10 Å.

Attorney Docket No.: 2003028-0051 Client Reference: MIT 6834/Ariad 022 US